Bluejay Diagnostics Inc
bluejaydx.comWhat Do They Do?
Develops a near-patient blood-testing system and single-use tests for hospital critical-care teams assessing sepsis.
10-K for FY2025, filed Mar 6, 2026Bluejay Diagnostics, Inc. (“Bluejay”) is a medical diagnostics company focused on improving patient outcomes in critical care settings…View ↗
Our Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP on the Symphony…View ↗
Our first product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the…View ↗
Who Are Their Customers?
If it receives FDA clearance, Bluejay plans to sell its tests and devices to emergency and intensive-care departments at U.S. hospitals and to long-term acute-care facilities, both directly and through distribution channels.
10-K for FY2025, filed Mar 6, 2026Sales and MarketingView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$2.3MView ↗
- ▲ +19% (Loss)
- vs −$2M in Q2 FY2025
-
Sep 1, 2026
Adds Lovell as distributor for government healthcare procurement
Lovell will distribute products exclusively for certain federal procurement opportunities and non-exclusively in other government markets, after regulatory authorization.
Sources
8-K, filed Sep 8, 2026
On September 1, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into a Distribution, Co-Marketing & Strategic Partnership Agreement…View ↗
A sharper focus on sepsis
The older report described the platform as addressing sepsis, cardio-metabolic diseases, cancer and other rapid-testing needs; the latest report prioritizes its sepsis test, with tests for other diseases framed as future possibilities.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 6, 2026The Symphony platform and our initial biomarker test, Symphony IL-6 test, is well suited to address a subset of the global in vitro…View ↗
Who Do They Compete With?
Competes with Roche, Siemens, and Beckman Coulter
10-K for FY2025, filed Mar 6, 2026There are currently no FDA cleared or approved IL-6 tests on the market. There are IL-6 tests granted under FDA Emergency Use Authorization…View ↗
Loading...
